ABSTRACT
Objective To discuss the clinical significance of the changes of endothelin-1 and troponin-1 levels in kawasaki disease after acute stage. Methods 60 patients of kawasaki disease in which 12 cases of patient were complicated with coronary artery disease and 48 cases of patient who were not complicated with coronary artery disease were enrolled this study. Blood plasma endothelin-1 and serum cardiac troponin I were determined in kawasaki disease acute phase and recovery phase and 30 healthy children. Results Acute phase ET-1 and cTnI [(90.19±3.43)ng/L, (1.35±0.14)μg/L] and recovery phase ET-1 and cTnI [(89.09±2.44)ng/L, (1.12±0.11)μg/L ] in coronary artery lesions of (CAL) group had no significant difference（P＞0.05）. The concentration values of ET-1, cTnI in no coronary artery lesions (NCAL) group of acute phase (64.49±4.78)ng/L,(0.62±0.02)μg/L were different with convalescent phase (50.47±4.49)ng/L,(0.07±0.05)μg/L. There were significant difference between the the two phases (P＜0.01). Plasma endothelin-1 and serum troponin I concentrations were positively correlated in acute phase of Kawasaki disease in children (r＝0.93,0.96,P＜0.01). Conclusions Plasma endothelin-1 and serum cardiac troponin I test for the diagnosis of Kawasaki disease with coronary artery disease may be early indicators of risk monitoring, they are valuable indexes in diagnosis and treatment of Kawasaki disease.
ABSTRACT
Objective To study the changes of neuron-specific-enolase (NSE), S100B protein and neuropeptide Y (NPY) levels in serum and cerebrospinal fluid of children with viral encephalitis and their clinical significance. Methods The NSE, S100B protein and NPY levels in the serum and cerebrospinal fluid of 50 children with viral encephalitiswere were measured, and another 20 children without central nervous system infection were selected as controls. Results The NSE, S100B protein and NPY levels in the serum and cerebrospinal fluid of children with viral encephalitis[serum: (18.90 ± 5. 50)μg/L, (0. 57 ±0. 26) μg/L, (267. 3 ± 54. 7 ) μg/L; GSF: ( 10. 45 ± 4. 40) μg/L, (0. 93 ± 0. 53 ) μg/L, (347.2 ± 60. 6) μg/L] were higher than those in control group [serum: ( 10. 35 ± 2. 49 ) μg/L, ( 10 ± 0. 06 ) μg/L, ( 67. 8 ±22.5)μg/L;GSF:(3.96 ± 1.57)μg/L,(0. 29 ±0. 18)μg/L,(102.6 ±38.9) μg/L] ( P <0.01). The levels of serum and CSF NSE S100B protein and NPY in critical patient[serum: (21.93 ±5.39)μg/L,(0.71 ±0. 31)μg/L, (32. 5 ± 62. 8) μg/L;GSF: (13.05 ±4.41)μg/L, (1.23 ± 0. 66) μg/L, (407.3 ±68. 1 ) μg/L] were higher than ordinary patients [serum: ( 15.93 ± 4. 02 ) μg/L, ( 0. 42 ± 0. 14 ) μg/L,(234.7 ±51.2)μ.g/L;GSF:(8.05 ± 1.77) μg/L,(0. 63 ±0.26)μg/L, (320.2 ±59.5) μg/L] ( P <0. 01 ). Conclusion NSE, S100B protein and NPY can be used to evaluate encephalitis condition, brain damage degree and prognosis of viral encephalitis.